FDO Partners LLC Reduces Stake in Zimmer Biomet Holdings, Inc. (ZBH)

FDO Partners LLC cut its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 56.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,648 shares of the medical equipment provider’s stock after selling 12,687 shares during the quarter. FDO Partners LLC’s holdings in Zimmer Biomet were worth $1,130,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of ZBH. Bronfman E.L. Rothschild L.P. boosted its holdings in Zimmer Biomet by 25.3% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock valued at $106,000 after purchasing an additional 167 shares during the period. FNY Managed Accounts LLC purchased a new position in Zimmer Biomet in the third quarter valued at $117,000. BB&T Investment Services Inc. purchased a new position in Zimmer Biomet in the second quarter valued at $144,000. Sandy Spring Bank boosted its holdings in Zimmer Biomet by 5.4% in the second quarter. Sandy Spring Bank now owns 1,288 shares of the medical equipment provider’s stock valued at $166,000 after purchasing an additional 66 shares during the period. Finally, Grove Bank & Trust boosted its holdings in Zimmer Biomet by 346.1% in the second quarter. Grove Bank & Trust now owns 1,316 shares of the medical equipment provider’s stock valued at $169,000 after purchasing an additional 1,021 shares during the period. 86.21% of the stock is owned by institutional investors and hedge funds.

ZBH has been the subject of a number of recent research reports. Jefferies Group reiterated a “buy” rating and issued a $136.00 target price on shares of Zimmer Biomet in a report on Friday, November 3rd. Gabelli initiated coverage on Zimmer Biomet in a report on Thursday, August 24th. They issued a “buy” rating and a $142.00 target price for the company. Oppenheimer set a $137.00 target price on Zimmer Biomet and gave the company a “buy” rating in a report on Monday, August 14th. SunTrust Banks set a $136.00 target price on Zimmer Biomet and gave the company a “buy” rating in a report on Wednesday, November 1st. Finally, Edward Jones upgraded Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Thursday, November 9th. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $133.71.

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) traded down $2.53 during midday trading on Friday, reaching $114.57. The company’s stock had a trading volume of 1,490,000 shares, compared to its average volume of 1,398,749. The stock has a market cap of $23,197.33, a P/E ratio of 14.20, a price-to-earnings-growth ratio of 1.78 and a beta of 1.15. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.47 and a quick ratio of 0.78. Zimmer Biomet Holdings, Inc. has a 12 month low of $99.59 and a 12 month high of $133.49.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.74 by ($0.02). The business had revenue of $1.82 billion for the quarter, compared to analysts’ expectations of $1.83 billion. Zimmer Biomet had a return on equity of 16.29% and a net margin of 8.36%. The firm’s quarterly revenue was down .8% on a year-over-year basis. During the same period last year, the firm earned $1.79 earnings per share. equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.03 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This news story was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.com-unik.info/2017/12/03/fdo-partners-llc-reduces-stake-in-zimmer-biomet-holdings-inc-zbh.html.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

What are top analysts saying about Zimmer Biomet Holdings Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zimmer Biomet Holdings Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit